https://www.bioworld.com/articles/727482-oncotartis-ot-82-enhances-venetoclax-efficacy-in-aml?v=preview
Venetoclax has shown good results for adult acute myeloid leukemia (AML) in combination with azacitidine, but there is increasing evidence of inherent and...
otvenetoclaxefficacyaml
https://www.ajmc.com/view/emerging-data-suggest-select-benefit-for-venetoclax-in-mds-ivo-carre-phd
Dec 7, 2025 - Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
emergingdatasuggestselectbenefit
https://pubmed.ncbi.nlm.nih.gov/34470049/
Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective,...
phasestudyvenetoclaxpluscarfilzomib
https://www.news-medical.net/news/20240326/ABT199venetoclax-synergism-with-thiotepa-enhances-cytotoxicity-of-chemo-drugs-in-AML-cells.aspx
A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity...
venetoclaxsynergismthiotepacytotoxicitychemo
https://www.medlineplus.gov/druginfo/meds/a616028.html
Venetoclax: learn about side effects, dosage, special precautions, and more on MedlinePlus
venetoclaxmedlineplusdruginformation
https://www.biospace.com/press-releases/oryzon-announces-first-patient-dosed-in-nci-sponsored-iadademstat-in-combination-with-venetoclax-and-azacitidine-clinical-trial-in-first-line-acute-myeloid-leukemia
announcesfirstpatientdosednci
https://www.news-medical.net/news/20150812/AbbVies-venetoclax-Phase-2-trial-meets-primary-endpoint-in-patients-with-relapsedrefractory-CLL-with-17P-deletion.aspx
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of...
primary endpointabbvievenetoclaxphasetrial